Compass Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 32
- Market Cap
- $173.3M
- Introduction
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
Compass Therapeutics Reveals Breakthrough Biomarker Data for Cancer Drug CTX-471
Compass Therapeutics presented biomarker data for CTX-471, showing a correlation between NCAM/CD56 expression and patient response, suggesting NCAM's potential as a selection marker for future trials.
© Copyright 2024. All Rights Reserved by MedPath